ArticleRadiation oncology (London, England)2013
Analysis of equivalent uniform dose (EUD) and conventional radiation treatment parameters after primary and re-irradiation of malignant glioma.
Article in Radiation oncology (London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Validation of the prognostic Heidelberg re-irradiation score in an independent mono-institutional patient cohort.Radiation oncology (London, England) · 2014Trial
- Using three-dimensional equieffective dose mapping to audit a methodology for calculating permitted doses for head and neck reirradiation.Physics and imaging in radiation oncology · 2025Article
- Dummy run for planning of isotoxic dose-escalated radiation therapy for glioblastoma used in the PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06).Clinical and translational radiation oncology · 2024Article
- Dosimetric feasibility analysis and presentation of an isotoxic dose-escalated radiation therapy concept for glioblastoma used in the PRIDE trial (NOA-28; ARO-2022-12).Clinical and translational radiation oncology · 2024Article
- The evolving role of reirradiation in the management of recurrent brain tumors.Journal of neuro-oncology · 2023Review
- Upstaging and Downstaging in Gliomas-Clinical Implications for the Fifth Edition of the World Health Organization Classification of Tumors of the Central Nervous System.Diagnostics (Basel, Switzerland) · 2023Article
- Dosimetric differences between intensity-modulated radiotherapy based on equivalent uniform dose and dose-volume optimization in stage III non-small cell lung cancer.American journal of translational research · 2022Article
- Dosimetric and biological comparisons of single planning and double plannings for bilateral lung cancer SBRT planning based on the Cyber-Knife system.Frontiers in oncology · 2022Article
- Current status and recent advances in reirradiation of glioblastoma.Radiation oncology (London, England) · 2021Review
- Potential Defects and Improvements of Equivalent Uniform Dose Prediction Model Based on the Analysis of Radiation-Induced Brain Injury.Frontiers in oncology · 2021Article
- Re-irradiation for recurrent high-grade gliomas: a systematic review and analysis of treatment technique with respect to survival and risk of radionecrosis.Neuro-oncology practice · 2019Article
- Timing of re-irradiation in recurrent high-grade gliomas: a single institution study.Journal of neuro-oncology · 2018Article
- A prospective study on neurocognitive effects after primary radiotherapy in high-grade glioma patients.International journal of clinical oncology · 2016Article
- Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?Oncotarget · 2016Review
- Use of a correlation analysis model in the optimization of intensity-modulated radiotherapy of prostate cancer.Experimental and therapeutic medicine · 2015Article
- Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients.Radiation oncology (London, England) · 2014Article
- Hippocampal EUD in primarily irradiated glioblastoma patients.Radiation oncology (London, England) · 2014Article
- Metachronous medulloblastoma and glioblastoma: Implications for clinical and technical aspects of re-irradiation.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation OncologyArticle
- Fractionated reirradiation of recurrent high-grade gliomas: Safety with higher reirradiation dose and larger targets.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRe-irradiation is a reasonable second treatment option for patients with recurrent malignant glioma (MG) after previous radio(chemo)therapy. However, only limited data is available allowing for a precise selection of patients suitable for re-treatment in regard to safety and efficacy.
methodsUsing the department database, 58 patients with two courses of percutaneous radiation were identified. Besides classical dose-volume histogram (DVH) parameters equivalent uniform dose (EUD) values were calculated for the tumor and organs at risk (OARs), retrospectively analyzed and correlated to survival outcome parameters. Cumulative EUD values were also calculated in all cases where previous OAR DVHs were available.
resultsMedian follow-up was 265 days and no relevant toxicity was observed after re-irradiation in our patient cohort during follow-up. Time interval between first and second irradiation was regularly above 6 months. As a conservative estimation of the cumulative EUD to the OARs, the EUDs of first and second irradiation were added. Median cumulative EUD to the optic chiasm was 48.8 Gy (range, 2.5-76.5 Gy), 57.4 Gy (range, 2.7-75.3 Gy) to the brainstem, 20.9/22.1 Gy (range, 0.0-68.3 Gy) to the right/left optic nerve and 73.8 Gy (range, 64.9-77.3 Gy) to the brain. No correlation between treated volume and survival was seen.
conclusionsThis study provides retrospective estimates on cumulative doses at the OARs. EUD values are derived and may serve as reference for further studies, including planning studies where specific constraints are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.